

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 39/00, C07K 16/18</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/02045</b> <b>(43) International Publication Date:</b> 23 January 1997 (23.01.97)
<b>(21) International Application Number:</b> PCT/GB96/01614 <b>(22) International Filing Date:</b> 5 July 1996 (05.07.96) <b>(30) Priority Data:</b> 9513733.7      5 July 1995 (05.07.95)      GB <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF BRISTOL [GB/GB]; Senate House, Tyndall Avenue, Clifton, Bristol BS8 1TH (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WILLIAMS, Neil, Andrew [GB/GB]; 16 Old Coach Road, Cross, Axbridge, Somerset BS26 2EF (GB). HIRST, Timothy, Raymond [GB/GB]; 30 Albert Road, Clevedon, North Somerset BS21 7RR (GB). NASHAR, Toufic, Osman [LB/GB]; University of Bristol, School of Medical Services, Dept. of Pathology & Microbiology, University Walk, Bristol BS8 1TD (GB). <b>(74) Agent:</b> NASH, David, Allan; Haseltine Lake & Co., Hazlitt House, 28 Southampton Buildings, Chancery Lane, London WC2A 1AT (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> THERAPEUTIC AGENTS AND AUTOIMMUNE DISEASES  <b>(57) Abstract</b>  There is disclosed the use, as an agent in the treatment or the prevention of an autoimmune disease, of: (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity. These agents may also be used in the treatment of human T cell leukaemia, in the prevention of transplant rejection or GVHD or in a vaccination method for vaccinating a mammalian subject.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

## THERAPEUTIC AGENTS AND AUTOIMMUNE DISEASES

This invention relates to therapeutic agents for use in the treatment of mammalian, particularly human, autoimmune diseases. The invention also relates to  
5 therapeutic agents useful in the treatment of human leukaemias of a T cell origin, as so-called "vaccine carriers", and as agents for use in the prevention of human transplantation rejection and graft versus host disease (GVHD).

10 In an article entitled "Morphologic and Functional Alterations of Mucosal T Cells by Cholera Toxin and its B subunit" by Charles O. Elson et al., The Journal of Immunology, 1995, 154; 1032-1040 it is disclosed that the cholera toxin (Ctx) and the CtxB subunit inhibit  
15 CD8<sup>+</sup> and CD4<sup>+</sup> T cells.

Reference is also made to the paper entitled "Prevention of Acute Graft-Versus-Host Disease by Treatment with a Novel Immunosuppressant" by B. Yankelevich et al., The Journal of Immunology, 1995,  
20 154: 3611-3617. This identifies CtxB as an agent for use in bone marrow transplantation for the prevention of acute graft-versus-host disease (GVHD).

WO 95/10301 discloses an immunological tolerance-inducing agent comprising a mucosa-binding molecule  
25 linked to a specific tolerogen.

As used herein, the term "Ctx" refers to the cholera toxin and "CtxB" to the B subunit of the cholera toxin. In other texts, these may sometimes be identified as "CT" or "Ct" and "CTB" or "CtB"  
30 respectively. The term "Ctx" herein means the *E. coli* heat labile enterotoxin, and "CtxB" is the B subunit of Ctx. In other texts, these may sometimes be identified as "LT" or "Lt" and "LTB" or "LtB" respectively.

The basis for all aspects of the present invention  
35 is the finding that CtxB (the pure B-subunit of the *E. coli* heat labile enterotoxin) binds to GM1-ganglioside

SUBSTITUTE SHEET (RULE 26)

-2-

receptors which are found on the surfaces of mammalian cells, and that this binding induces differential effects on lymphocyte populations, including a specific depletion of CD8<sup>+</sup> T cells and an associated activation of B cells. These effects are absent when a mutant EtxB protein lacking GM1 binding activity is employed.

#### Autoimmune disease

Autoimmunity is the term used to describe the mechanism by which the body generates an immune response to self-antigens.

In accordance with a first aspect of the invention, there is provided:

- (i) an agent having GM-1 binding activity, other than Ctx or EtX, or the B subunits of Ctx and EtX; or
- (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;

for use as an agent in the treatment or the prevention of an autoimmune disease.

Agents in accordance with the present invention have been found to modulate lymphocyte populations leading to the induction of apoptosis in CD8<sup>+</sup> T cells, the enhanced activation of CD4<sup>+</sup> cells and polyclonal activation of B cells. These events are likely to shift the immune response towards induction of Th2 associated cytokines. Such responses to self or cross-reacting antigens are understood to mediate protection for certain autoimmune diseases.

In a first embodiment of this first aspect of the present invention, the agent is used in a method of treating an autoimmune disease which is in progress. In this embodiment, the agent is administered to a patient with or without co-administration of a self or cross-reacting antigen. Administration of the agent in accordance with this embodiment of the first aspect of the invention modulates the nature of the immune

-3-

response towards the self-antigen away from the activation of disease-causing inflammation and hence protects against autoimmune disease.

In a second embodiment of this first aspect of the present invention, the agent is used in a method for the "vaccination" of a mammalian subject against an autoimmune disease, in which the agent is co-administered with the self or cross-reacting antigenic determinant (or a combination of different self or cross-reacting antigenic determinants) associated with said disease. In such a manner, the subject's immune response to the self-antigen or cross-reacting antigen is switched away from the activation of pathogenesis, which therefore protects against a future autoimmune response to the self-antigen.

In this first aspect of the invention, the therapeutic agent and the self or cross-reacting antigenic determinant are, or may be, co-administered to the subject. By this we mean that the site and time of administration of each of the therapeutic agent and the antigenic determinant are such that the necessary modulation of the immune system is achieved. Thus, whilst the therapeutic agent and the antigenic determinant may be administered at the same moment in time and at the same site, there may be advantages in administering the therapeutic agent at a different time and to a different site from the antigenic determinant.

Whilst single doses of the therapeutic agent and the antigenic determinant may be satisfactory, multiple doses are contemplated within the scope of this aspect of the invention.

In this second embodiment of the first aspect of the invention, the therapeutic agent and the antigenic determinant may be linked, for example covalently linked, to form a single active agent, although separate administration, in which the therapeutic agent

**SUBSTITUTE SHEET (RULE 26)**

-4-

and the antigenic determinant are not so linked is preferred because it enables separate administration of the different moieties.

Specific autoimmune diseases which may be treated  
5 in accordance with this aspect of the present invention are the autoimmune diseases where pathology is associated with cell-mediated immunity, such as rheumatoid arthritis, multiple sclerosis and diabetes.

Additionally, under this first aspect of the  
10 present invention, there is provided the use of Ctx, Etx or the B subunit of Ctx or Etx, for the manufacture of a medicament for use as an agent for the prevention of an autoimmune disease.

Also provided is a pharmaceutical composition for  
15 the treatment of a human autoimmune disease comprising  
(i) an agent having GM-1 binding activity; or  
(ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;  
20 and a pharmaceutically acceptable carrier or diluent therefor.

The pharmaceutical composition of this aspect of the invention may be formulated to be delivered by a mucosal route, for example as a nasal spray, or  
25 parenterally in which the composition is formulated in an injectable form, for delivery by, for example, an intravenous, intramuscular or subcutaneous route.

The pharmaceutical composition may be formulated together with the appropriate self or cross-reacting  
30 antigen. Alternatively, a kit may be provided comprising separate compositions for each of the therapeutic agent and the antigenic determinant.

Specific therapeutic agents which may be used in this aspect of the invention are EtxB and CtxB or  
35 mutants thereof retaining GM1 binding activity.

The agents for use in the first aspect of the

**SUBSTITUTE SHEET (RULE 26)**

-5-

present invention should preferably be substantially non-toxic, although some degree of toxicity may be tolerated in a severe therapy of this kind.

This first aspect of the invention extends to  
5 cover the use of all agents having GM1 binding activity, for use in the treatment of mammalian autoimmune disease, as well as those agents having an effect on GM-1 mediated intracellular signalling events, and which therefore mimic GM-1 binding agents.

10 Thus, this first aspect of the present invention is not limited to the use of EtxB protein as a therapeutic agent in the treatment of a human autoimmune disease. However, the use of the EtxB protein (which is a pentamer of five identical  
15 subunits) for such a treatment represents a preferred embodiment of the present invention. In addition to the wild type EtxB, this preferred aspect of the invention also extends to mutants of EtxB which have GM-1 binding activity as well as to other equivalent  
20 proteins, such as the cholera toxin B subunit (CtxB) and mutants thereof which have GM1 binding activity.

Other therapeutic agents for the treatment of autoimmune disease in accordance with the first aspect of this invention are humanised monoclonal antibodies,  
25 which bind GM1. Methods known in the art for identifying and preparing such agents are well known.  
T-lymphocyte leukaemias

According to a second aspect of this invention, there is provided:

- 30 (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or  
(ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;  
35 for use in the treatment of human leukaemias of a T cell origin, such as human leukaemias of a CD8 T cell

-6-

origin.

The agents for use in the second aspect of the present invention should preferably be substantially non-toxic, although some degree of toxicity may be tolerated in a severe therapy of this kind.

Additionally, under this second aspect of the present invention, there is provided the use of Ctx or Etx, or the B subunits of Ctx and Etx for the manufacture of a medicament for treatment of human leukaemias of a T cell origin, such as human leukaemias of a CD8 T cell origin.

Also provided is a pharmaceutical composition for the treatment of human leukaemias of a T cell origin comprising

- (i) an agent having GM-1 binding activity; or
  - (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;
- and a pharmaceutically acceptable carrier or diluent therefor.

The pharmaceutical composition of this aspect of the invention may be formulated to be delivered by a mucosal route, for example as a nasal spray, or parenterally in which the composition is formulated in an injectable form, for delivery by, for example, an intravenous, intramuscular or subcutaneous route.

This second aspect of the invention extends to cover the use of all agents having GM1 binding activity, for use in the treatment of human leukaemias of a T cell origin, as well as those agents having an effect on GM-1 mediated intracellular signalling events, and which therefore mimic GM-1 binding agents.

Thus, this second aspect of the present invention is not limited to the use of EtxB protein as therapeutic agents in the treatment of human T cell leukaemias. However, the use of the EtxB protein for

**SUBSTITUTE SHEET (RULE 26)**



- 7 -

such a treatment represents a preferred embodiment of the present invention. In addition to the wild type EtxB, this preferred aspect of the invention also extends to mutants of EtxB which have GM-1 binding activity as well as to other equivalent proteins, such as the cholera toxin B subunit (CtxB) and mutants thereof which have GM1 binding activity.

Other alternative therapeutic agents for the treatment of these diseases in accordance with this aspect of the invention are humanised monoclonal antibodies, which bind GM1. Methods known in the art for identifying and preparing such agents are well known.

#### Transplant rejection and GVHD

In accordance with a third aspect of this invention, there is provided:

- (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or
- (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;

for use as a therapeutic agent for the prevention/treatment of transplant rejection or GVHD.

Additionally, under this third aspect of the present invention, there is provided the use of Ctx or Etx or the B subunit of Etx or Ctx for the manufacture of a medicament for the prevention of transplant rejection or GVHD.

In preferred embodiments of this aspect of the invention, the therapeutic agents described may be used in the prevention of solid organ transplant rejection, either allogeneic or xenogeneic. They may also be employed in the prevention of acute graft versus host disease (GVHD), for example during bone marrow transplantation procedure.

In embodiments of this aspect of the invention

- 8 -

where the patient is treated prior to transplantation, the therapeutic agent would be co-administered with alloantigen or xenoantigen. In embodiments in which the patient is treated after transplantation, the  
5 therapeutic agent is employed without co-administration of antigen.

In the embodiment of this aspect of the invention, where the therapeutic agent and allo- or xeno-antigenic determinant are co-administered to the subject, we mean  
10 that the site and time of administration of each of the therapeutic agent and the antigenic determinant are such that the necessary modulation of the immune system is achieved. Thus, whilst the therapeutic agent and the antigenic determinant may be administered at the  
15 same moment in time and at the same site, there may be advantages in administering the therapeutic agent at a different time and to a different site from the antigenic determinant. Furthermore, the therapeutic agent and the antigenic determinant may be covalently  
20 linked to form a single active agent, although separate administration, in which the therapeutic agent and the antigenic determinant are not so linked is preferred because it enables separate administration of the different moieties.

25 Whilst single doses of the therapeutic agent and the antigenic determinant may be satisfactory, multiple doses are contemplated within the scope of this aspect of the invention.

In this aspect of the invention, where the agent  
30 is being used in the prevention of GVHD, the agent would normally be applied direct to the cells, for example bone marrow cells, to be transplanted.

The agent is preferably substantially non-toxic, although some degree of toxicity may be tolerated in  
35 severe therapies of this kind.

Also provided is a pharmaceutical composition for

**SUBSTITUTE SHEET (RULE 26)**

-9-

use in the treatment of transplant rejection,  
comprising

- (i) an agent having GM-1 binding activity; or
  - (ii) an agent having an effect on GM-1 mediated  
5 intracellular signalling events, but no GM-1  
binding activity;
- and a pharmaceutically acceptable carrier or diluent  
therefor.

The pharmaceutical composition of this aspect of  
10 the invention may be formulated to be delivered by a  
mucosal route, for example as a nasal spray, or  
parenterally in which the composition is formulated in  
an injectable form, for delivery by, for example, an  
intravenous, intramuscular or subcutaneous route.

15 The pharmaceutical composition may be formulated  
together with the appropriate allo- or xeno-antigeneic  
determinant. Alternatively, a kit may be provided  
comprising separate compositions for each of the  
therapeutic agent and the antigenic determinant.

20 This third aspect of the invention extends to  
cover the use of all agents having GM1 binding  
activity, for use in the prevention/treatment of  
transplant rejection or GVHD, as well as those agents  
having an effect on GM-1 mediated intracellular  
25 signalling events, and which therefore mimic GM-1  
binding agents.

Thus, this third aspect of the invention is not  
limited to the use of EtxB protein as a therapeutic  
agent in the treatment of a transplant rejection.  
30 However, the use of the EtxB protein (which is a  
pentamer of five identical subunits) for such a  
treatment represents a preferred embodiment of the  
present invention. In addition to the wild type EtxB,  
this preferred aspect of the invention also extends to  
35 mutants of EtxB which have GM-1 binding activity as  
well as to other equivalent proteins, such as the

**SUBSTITUTE SHEET (RULE 26)**

-10-

cholera toxin B subunit (CtxB) and mutants thereof which have GM1 binding activity.

Other alternative therapeutic agents for the treatment of transplant rejection in accordance with the invention are humanised monoclonal antibodies, which bind GM1. Methods known in the art for identifying and preparing such agents are well known.

#### Vaccination

CtxB and EtxB have already been suggested as so-called "vaccine carriers". It has now been discovered that the basis for this effect, in part, is the ability of EtxB to modulate lymphocyte populations (as discussed above) by binding to the GM-1 receptor.

Thus, in accordance with a fourth aspect of the present invention, there is provided:

- (i) an agent having GM-1 binding activity, other than Etx or Ctx or the B subunits of Etx or Ctx; or
  - (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;
- for use in the vaccination of a mammalian subject.

The agent is capable of modulating the immune response when delivered together with an unrelated foreign antigenic determinant. Where the agent is delivered parenterally, such immunomodulation is in terms of the immune response being "directed" in a particular desired direction. Where the agent is delivered mucosally with an unrelated antigen, as a so-called "mucosal adjuvant", the agent is capable of facilitating a mucosal immune response to the unrelated antigen. The antigen and agent may be delivered together as separate moieties, or may be linked together, for example by a covalent linkage.

The agent is preferably non-toxic. In addition, where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to

-11-

remain stable during transit through the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

5 Also provided is a pharmaceutical composition for use in the vaccination of a mammalian subject, comprising

- (i) an agent having GM-1 binding activity; or
- (ii) an agent having an effect on GM-1 mediated

10 intracellular signalling events, but no GM-1 binding activity;

and a pharmaceutically acceptable carrier or diluent therefor.

The pharmaceutical composition of this aspect of  
15 the invention may be formulated to be delivered by a mucosal route, for example as a nasal spray, or parenterally in which the composition is formulated in an injectable form, for delivery by, for example, an intravenous, intramuscular or subcutaneous route.

20 The pharmaceutical composition may be formulated together with the appropriate antigenic determinant. Alternatively, a kit may be provided comprising separate compositions for each of the therapeutic agent and the antigenic determinant.

25 This fourth aspect of the invention extends to cover the use of all agents having GM1 binding activity, as immunomodulators, as well as those agents having an effect on GM-1 mediated intracellular signalling events, and which therefore mimic GM-1  
30 binding agents.

Thus, this fourth aspect of the invention is not limited to the use of EtxB protein as an immunomodulator. However, the use of the EtxB protein (which is a pentamer of five identical subunits) in  
35 such a way represents one embodiment of the present invention. In addition to the wild type EtxB, this

SUBSTITUTE SHEET (RULE 26)

-12-

preferred aspect of the invention also extends to mutants of EtxB which have GM-1 binding activity as well as to other equivalent proteins, such as the cholera toxin B subunit (CtxB) and mutants thereof  
5 which have GM1 binding activity.

Other alternative therapeutic agents for use as an immunomodulator in accordance with this aspect of the invention are humanised monoclonal antibodies, which bind GM1. Methods known in the art for identifying and  
10 preparing such agents are well known.

When the therapeutic agent of the invention is a protein, such as the EtxB subunit or the CtxB subunit, it may be produced, for use in all aspects of this invention, by a method in which the gene or genes  
15 coding for the specific polypeptide chain (or chains) from which the protein is formed, is inserted into a suitable vector and then used to transfect a suitable host. For example, the gene coding for the polypeptide chain from which EtxB assemble may be inserted into,  
20 for example, plasmid pMMB68, which is then used to transfect host cells, such as Vibrio sp.60. The protein is purified and isolated in a manner known per se. Mutant genes expressing active mutant EtxB protein may then be produced by known methods from the wild  
25 type gene.

As previously stated, agents having GM-1 binding activity, such as specifically designed humanised monoclonal antibodies, may be designed and produced as outlined above, by methods which are known in the art.

30 In all aspects of the invention, the agent having GM1 binding activity may also be capable of cross-linking GM1 receptors. EtxB is one such agent which is capable of cross-linking GM1 receptors by virtue of its pentameric form.

35 The invention will now be illustrated by reference to the accompanying drawings and the following

**SUBSTITUTE SHEET (RULE 26)**

-13-

examples.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 represents an analysis of physico-chemical properties of EtxB and a mutant form of EtxB,  
5 (EtxB(G33D));

Figure 2 illustrates that receptor binding by EtxB is essential for its potent immunogenicity *in vivo*;

Figure 3 illustrates the kinetics of lymphocyte proliferation following injection of mice with EtxB;

10 Figure 4 illustrates that EtxB causes increased activation of B cells;

Figure 5 illustrates that EtxB causes increased activation of CD4<sup>+</sup> T cells and depletion of CD8<sup>+</sup> cells.

Figure 6 shows the selective depletion of OVA-  
15 responsive CD8<sup>+</sup> T cells by EtxB;

Figure 7 shows that receptor binding by EtxB induces alterations in lymphocyte nuclear morphology characteristic of cells undergoing apoptosis;

Figure 8 shows EtxB receptor-mediated apoptosis of  
20 CD8<sup>+</sup> T cells as measured by cell cycle analysis;

Figures 9a and 9b show the results of experiments conducted to show that GM-1 binding by EtxB inhibits the development of collagen induced arthritis in an animal model;

25 Figure 10 shows the results of an experiment conducted to illustrate that EtxB but not EtxB(G33D) induces apoptosis in a population of normal human peripheral blood mononuclear cells; and

Figure 11 shows the results of an experiment which  
30 shows that cross-linking of GM1 leads to apoptosis in a proportion of murine CTL cells.

#### DETAILED DESCRIPTION OF THE DRAWINGS

##### Figure 1

Analysis of physico-chemical properties of EtxB and  
35 EtxB (G33D).

(A) SDS-PAGE analysis of EtxB or EtxB (G33D): 5µg

-14-

of each protein were analysed under reducing conditions in the presence of  $\beta$ -mercaptoethanol with or without prior heating. Lane 1, wild type EtxB, unheated. Lane 2, EtxB (G33D), unheated. Lane 3; wild type EtxB, heated at 95°C. Lane 4, EtxB (G33D), heated at 95°C. Molecular weight standards (BioRad) are shown on the left-hand side of the panel.

(B) Determination of apparent molecular mass of EtxB and EtxB (G33D) by gel filtration chromatography: standard curve (circles) was generated using, from top to bottom: bovine serum albumin (66 kDa), hen egg albumin (45 kDa), bovine erythrocyte carbonic anhydrase (29 kDa) and horse heart cytochrome c (12.4 kDa); EtxB and EtxB (G33D) eluted with apparent molecular masses of 36kDa and 38kDa respectively;  $V_e$ -elution volume of the protein,  $V_o$ -void volume of the gel filtration column.

(C) ELISA for comparative binding of EtxB and EtxB (G33D) to ganglioside GM1: plates were coated with GM1, blocked and incubated with 1 $\mu$ g/ml of either EtxB or EtxB (G33D) diluted serially (3 fold) from 1 $\mu$ g/ml.

### Figure 2

**Receptor binding by EtxB is essential for its potent immunogenicity in vivo.**

BALB/c mice (4 in each group) were either injected s.c. with EtxB or EtxB (G33D) in PBS or given the proteins orally in bicarbonate buffer. Sera were analysed 10 days following two s.c. injections (A) or 1 week following 3 oral doses (B), and gut secretions were analysed 1 week following 3 oral doses (C). No reaction was detected in samples from control mice (not shown). Results are expressed as mean IgG antibody titre in serum, while IgA in gut secretion is expressed as 'specific activity' as described below.

### Figure 3

**Kinetics of lymphocyte proliferation**



-15-

Mice were injected i.p. with 30  $\mu$ g of EtxB (G33D) in complete Freund's adjuvant. MLNs were isolated 10 days later and cells were incubated in the absence of antigen (open square) or in the presence of 80  $\mu$ g/ml EtxB (filled triangles), EtxB (G33D) (open triangles) or their disassembled monomeric forms of EtxB (filled circles) and EtxB (G33D) (open circles) generated by heating at 95°C. The last 6 hour on each sampling day cells were pulsed with 1 $\mu$ Ci of (<sup>3</sup>H) Thd. Data represents mean cpm and SEM of triplicate wells.

**Figure 4****EtxB causes increased activation of B cells.**

Mice were immunized with EtxB (G33D) in CFA. Cells were isolated from MLN 10 days later and incubated in the presence of 80 $\mu$ g/ml of either EtxB or EtxB (G33D) or a mixture of 40 $\mu$ g/ml of each protein. Cells were labelled with biotinylated anti-CD25 (7D4) and Phycoerythrin (PE) anti-B220 (Ra3-6D2). Streptavidin FITC was used as a secondary antibody conjugate. Controls for the antibodies were also included (not shown). Dual flow cytometric analysis was performed on day 4 of proliferation.

**Figure 5****EtxB causes increased activation of CD4<sup>+</sup>T cells and depletion of CD8<sup>+</sup>T cells.**

The immunization procedure, cell isolation and the in vitro challenge are as described in the legend of Fig. 4. To detect CD25, biotinylated anti-CD25 (7D4) and Streptavidin FITC were used. To detect CD4 and CD8, FITC labelled anti-CD4 (RNRM4-5) and FITC labelled anti-CD8 $\alpha$  (53-6.7) were used. Appropriate controls for the antibodies were included (not shown).

**Figure 6****Selective depletion of OVA-responsive CD8<sup>+</sup> T cells by EtxB**

Cultures of cells from MLN taken from OVA-primed

-16-

mice were established for 5 days, in the absence of antigen or in the presence of OVA + EtxB, OVA + EtxB(G33D) or OVA alone at 100  $\mu$ g OVA and 40  $\mu$ g/ml each of EtxB or EtxB(G33D) or 100  $\mu$ g OVA alone. Cells were  
5 labelled with the following rat antibodies: FITC-anti-CD4 or FITC-anti-CD8 $\alpha$  and both with biotin-anti-CD25 (IL-2R $\alpha$ ) followed by Streptavidin-phycoerythrin. Non-stained cells or cells stained with the second antibody alone were also included as controls. Cells were  
10 analysed by FACS (Becton Dickinson). The higher increase in the proportion of total cells which are CD25+ in cultures containing EtxB compared with other treatments is due to the presence of higher proportion of B cells expressing this marker (not shown). The  
15 scale of fluorescence intensity is log.

**Figure 7**

**Receptor binding by EtxB induces alterations in lymphocyte nuclear morphology characteristic of cells undergoing apoptosis.**

20 MLNC comprising >90% CD3 $^{+}$  T cells and depleted of macrophages were incubated for 18 h with either 80  $\mu$ g/ml EtxB or with 80  $\mu$ g/ml EtxB(G33D) and stained with acridine orange. Cells were examined under conventional or confocal fluorescence microscopy (Leica TCS 4D). A  
25 representative microscopic field (x 540) for each treatment is shown [EtxB, left hand panel; EtxB (G33D), right hand panel]. Cells which were incubated in the absence of antigen gave similar results to those treated with EtxB(G33D) (not shown).

**Figure 8**

**EtxB receptor-mediated apoptosis of CD8 $^{+}$  T cells as measured by cell cycle analysis.**

The proportion of CD4 $^{+}$  and CD8 $^{+}$  SPLTC in the sub-G $_0$ /G $_1$  stage of the cell cycle was determined by flow  
35 cytometric analysis of the DNA content following staining with propidium iodide. SPLTC were isolated

-17-

from the spleen by negative selection as described above. The cells were treated for 18 h with: (a) no antigen, (b) 80  $\mu$ g/ml EtxB(G33D) or (c) 80  $\mu$ g/ml EtxB and then stained with FITC-rat anti-CD4 or FITC-rat anti-CD8 $\alpha$ . The cells were subsequently stained with propidium iodide. The proportion of cells co-stained with propidium iodide was determined by gating on cells stained with either anti-CD4 or anti-CD8 antibodies. This experiment has been carried out on cells, results of which are also reported in Figure 7 and Table 3.

### Examples

#### **Example 1**

This example illustrates the requirement for GM-1 binding to induce differential effects on lymphocyte populations.

### Materials and Methods

#### **Generation of a receptor-binding mutant of EtxB**

A Gly-33 to Asp substitution was introduced into the receptor binding site of human EtxB using plasmid pTRH29, a derivative of the phagemid vector pBluescript IIKS+, that contains the genes for the A- and B-subunits of Etx (Yu, J., Webb, H. & Hirst, T.R. (1992), Molec. Microbiol. 6, 1949-1958). Mutagenesis was performed with an *in vitro* oligonucleotide-directed mutagenesis kit (Amersham International) using single-stranded pTRH29 as a template and a synthetic oligonucleotide (5'-TCTCTTTTATCTGCCATCG-3') (from the Microanalytical Facility, IAPGR, Cambridge Research Station, UK) as the mutagenic primer. The correct Gly to Asp substitution was confirmed by dideoxy sequencing using Sequenase II (United States Biochemical Corp.) and the resultant plasmid was designated pTRH56. The mutant etxB gene from pTRH56 was excised, using EcoRI and SpeI restriction enzymes, and inserted into pMMB68 (Sandkvist, M., Hirst, T.R. & Bagdasarian, M. (1987) J.

-18-

Bacteriol. 169, 4570-4576) to yield a broad host range expression vector, pTRH64 expressing EtxB(G33D).

### Antigens

Wild-type EtxB and EtxB(G33D) were purified from  
5 culture supernatants of *Vibrio* sp.60 (pMMB68) and  
*Vibrio* sp.60 (pTRH64), respectively, using a  
modification of the method reported by Amin and Hirst  
(Amin, T., & Hirst, T.R. (1994) Prot. Express. and  
Purif. 5, 198-204). Briefly, proteins were purified by  
10 diafiltration and hydrophobic interaction  
chromatography and concentrated by anion-exchange  
chromatography. The protein solutions were desalted on  
a PD10 column (Pharmacia, UK) equilibrated with  
phosphate buffered saline (PBS; 10mM sodium phosphate,  
15 150 mM NaCl, pH7.4) and stored at -30°C.

The purity of EtxB and EtxB(G33D) were confirmed  
by SDS polyacrylamide gel electrophoresis. The  
molecular mass of the individual monomers were  
confirmed by laser desorption mass spectrometry  
20 (Protein Science Facility, University of Kent).

Apparent molecular masses of EtxB and EtxB(G33D)  
were determined by gel filtration chromatography using  
a SMART system (Pharmacia). Proteins were eluted from a  
Superdex 75 PC 3.2/30 column in PBS, pH7.5.

25 Irreversible denaturation of B subunit pentamers,  
for use in lymphocyte proliferation assays (see below),  
was achieved by heating the proteins at 95°C for 5 min.

### Animals, sample collection and immunization protocols

BALB/c mice (H-2<sup>d</sup>; high responder to EtxB) of 7-12  
30 weeks of age were purchased from Charles River  
Laboratories and maintained at the University of Kent  
animal house. Antibody responses to EtxB or EtxB(G33D)  
were measured after s.c. injection of mice with 30µg of  
protein in PBS, followed by boosting 10 days later.  
35 Another group of mice were given the same protein dose  
orally in sodium bicarbonate (50µg/ml) on 3 occasions,

**SUBSTITUTE SHEET (RULE 26)**

-19-

and at one week intervals. Control mice were given PBS. Blood was collected 10 days following the last s.c. injection or one week following the last oral feeding. Gut secretions from live mice were isolated  
5 in a protease inhibitor solution as previously described (Elson, C.O., Ealading, W. & Lefkowitz, J. (1984) J Immunol. Meth. 67, 101- 108), one week following the last feeding. Samples were then sonicated and clarified by centrifugation (13,226 x g,  
10 10 min, at 4°C).

For the proliferative assays, mice were injected i.p. with 30µg of EtxB or EtxB(G33D) in complete Freund's adjuvant (CFA) and the mesenteric lymph nodes isolated 10 days later. Control unimmunized mice were  
15 also included and their lymph nodes isolated in a similar manner.

#### Enzyme Linked Immunosorbent Assays (ELISAs)

Binding of EtxB or EtxB(G33D) to GM1 was examined by a GM1-ELISA (Amin, T., & Hirst, T.R. (1994) Prot.  
20 Express. and Purif. 5, 198-204).

Sera and gut secretions were examined for the presence of anti-B subunit IgG and IgA antibodies by ELISA's in which samples were applied to microtitre plates (Immulon I, Dynateck, USA) coated with 5µg/ml of  
25 either EtxB or EtxB (G33D) in PBS. Anti-B subunits IgA antibodies in gut secretion supernatants were extrapolated from a standard curve made by coating 2 rows of wells on each plate with 1µg/ml rabbit anti-mouse IgA (α chain specific; Zymed Lab, USA) in  
30 PBS followed by addition of 1µg/ml of mouse myeloma IgA (MOPC 315, Sigma, USA). To measure total IgA, wells were coated with rabbit anti-mouse IgA followed by addition of gut secretion supernatants. All samples were serially diluted. Goat anti-mouse IgG (Fc  
35 fragment specific; Jackson Lab., USA) or goat anti-mouse IgA (α chain specific; Sigma) peroxidase

SUBSTITUTE SHEET (RULE 26)

-20-

conjugate were diluted and added to all wells. The anti-B subunit IgG titer, giving an  $A_{450nm} \geq 0.2$ , was determined. The IgA anti-B subunit response for each of EtxB and EtxB (G33D) in gut secretions was  
5 calculated as "IgA specific activity" [mean IgA anti-B subunit ( $\mu\text{g/ml}$ )/total IgA ( $\mu\text{g/ml}$ )].

An ELISA method for measuring cytokine levels of IL-2, IL-4, IL-5, IL-10 and IFN- $\gamma$  was used, as described previously (Harper, H.M., PhD thesis,  
10 Univeristy of Bristol (1995)). Briefly, microtiter plates were coated with rat antibodies to mouse IL-2, IL-4, IL-5, IL-10 and IFN- $\gamma$ . Plates were blocked with 2% (w/v) bovine serum albumin. Supernatants from culture medium were added to wells and diluted down.  
15 One row on each plate for each cytokine contained a standard amount of recombinant cytokines. Plates were then incubated with 0.5 $\mu\text{g/ml}$  of biotinylated anti-cytokine monoclonal antibodies followed by addition of avidine-peroxidase and  
20 3,3',5,5'-Tetramethylbenzidine (TMB) substrate and read at  $A_{405nm}$ .

#### Lymphocyte proliferation assay

Mice were sacrificed by cervical dislocation, mesenteric lymph nodes were excised aseptically and  
25 minced through a stainless steel mesh into Hank's balanced salt solution (HBSS) (Flow Laboratories, Irvine, Renfrewshire, UK.). Cells were washed by centrifugation (500 x g, 10 min, 4°C) in HBSS and resuspended in modified Eagle's medium (Flow) to which  
30 20mM Hepes (Flow), 100 IU Penicillin, 100 $\mu\text{g/ml}$  Streptomycin, 4mM L-glutamine (Flow) and 2-mercaptoethanol had been added (complete medium). Fresh autologous normal mouse serum from unimmunized mice was added to a final concentration of 0.5% (v/v).  
35 Cultures contained  $2 \times 10^6$  viable cells/ml in either 2 ml volumes in 24-well plates or 8 ml volumes in 25 cm<sup>3</sup>

**SUBSTITUTE SHEET (RULE 26)**

-21-

flasks (Nunc A/S, Roskilde, Denmark) and were established in the presence and absence of antigens as indicated in the figures legend. Cultures were incubated at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> and 95% air for 6 days. At desired timepoints, 0.1 ml samples were removed from the cultures and transferred to 96 well U-bottomed plates (Nunc) and pulsed with 1 µCi/well of [<sup>3</sup>H]-Thd (Amersham, U.K) for 6 h before harvesting (Mach III harvesting 96 Tomtec, Orange, Conn. USA) and counting by standard liquid scintillation 1450 Micro β plus, LKB-Wallac, Turku, Finland). Similarly, 0.5 ml of supernatant was sampled from cultures for cytokine analysis. Cells were pelleted and the supernatants stored at - 68°C until analysed.

#### Phenotypic analysis of cultured cells

Cultured cells harvested on day 4 of culture were washed and viable cells recovered at the interface of a HBSS/18% metrizamide (Nyegaard and Co., Oslo, Norway) gradient following centrifugation at 500 xg for 15 min at 20°C. Cells were washed twice and resuspended in HBSS containing 0.2 % sodium azide (Sigma) and 10% normal rat serum. The following rat antibodies (Pharmingen, San Diego, USA) were used: fluorescein isothiocyanate (FITC) labelled anti-CD4 (RNRM4-5), FITC labelled anti-CD8 (53-6.7), biotin-labelled anti-CD25 (7D4) and Phycoerythrin (PE) labelled anti-B220 (RA3-6D2). Additionally, for the biotin-labelled antibodies Streptavidin-PE or Streptavidin-FITC (Serotech, UK) were used. All antibodies were diluted in HBSS containing azide and used at predetermined concentrations. 200 µl of 2 x 10<sup>6</sup> cells and 200 µl of each the antibodies were mixed and incubated on ice for 30 min. When Streptavidin -PE or FITC secondary antibodies were required cells were incubated with these antibodies for additional 30 min. Appropriate

**SUBSTITUTE SHEET (RULE 26)**

-22-

controls for FITC and PE antibodies were also included. Cells were washed with HBSS and then analysed by 2 flow cytometry (Becton Dickinson).

### Results

#### 5 Generation and characterization of a receptor binding mutant of EtxB

A Gly to Asp substitution was introduced into the B subunit of *E. coli* heat-labile enterotoxin by oligonucleotide-directed mutagenesis of EtxB, in order  
10 to generate a mutant B subunit defective in receptor recognition. The mutant protein, designated EtxB(G33D), and wild type EtxB were purified to homogeneity (see Materials and Methods). The molecular mass of purified EtxB and EtxB(G33D) were determined by  
15 laser desorption mass spectrometry. Masses were within 20 Da of the theoretical masses of 11702 and 11760 Da for monomeric EtxB and EtxB (G33D), respectively. When analysed by SDS-PAGE without prior heating, both wild-type EtxB and EtxB(G33D) migrated as discrete  
20 stable oligomers, with apparent molecular weights of 42 kDa and 56 kDa (Fig.1A, lane 1 and lane 2, respectively). The observed electrophoretic mobility and SDS-stability of EtxB is a characteristic property of the B subunit pentamer (see Sandkvist, M., Hirst,  
25 T.R. & Bagdasarian, M. (1987) J. Bacteriol. 169, 4570-4576). The slower electrophoretic mobility of oligomeric EtxB(G33D) is not due to a difference in the number of constituent B subunit monomers, since both pentameric EtxB and EtxB(G33D) exhibited similar  
30 retention times when analysed by high resolution gel filtration chromatography. Thus, the discrepancy in the electrophoretic mobility of the EtxB(G33D) oligomer with respect to wild-type EtxB, is likely to be due to the introduced negatively charged Asp residue causing a  
35 reduction in SDS binding and a subsequent slower migration.

SUBSTITUTE SHEET (RULE 26)



-23-

EtxB and EtxB(G33D) were also compared for their stability in low pH buffers, resistance to 1.0 mg/ml of either trypsin or proteinase K, and relative reactivity towards a panel of anti-B subunit monoclonal and polyclonal antibodies. In each of these tests EtxB(G33D) exhibited identical properties to wild-type EtxB. It is therefore concluded that a Gly to Asp substitution at residue 33 in EtxB does not alter the oligomeric configuration, SDS, pH or protease stability, or antibody reactivity compared with wild-type EtxB.

The ability of EtxB(G33D) to bind to its receptor GM1, was evaluated using a GM1-ELISA (Fig. 1C). This showed a highly significant reduction in the ability of the mutant to bind GM1 compared with the wild type protein (> 99% reduction in the  $A_{450nm}$  reading). Furthermore, in contrast to wild type EtxB, EtxB(G33D) failed to bind to CHO cells when examined by immunofluorescence. It is concluded that EtxB(G33D) is defective in its capacity to bind GM1 ganglioside, *in vitro* and *in situ*.

**The potent immunogenicity of EtxB *in vivo* is dependent on receptor binding**

The importance of receptor binding in the immunogenicity of EtxB was evaluated in mice following either oral delivery or s.c. injection of EtxB or EtxB(G33D) in PBS. Oral delivery of EtxB resulted in detection of a high IgG antibody titer in serum and IgA antibody activity in gut secretions (Fig. 2). In contrast, a similar regime of oral immunization with EtxB(G33D) failed to generate any detectable antibody activity. EtxB(G33D) did induce a serum antibody response following s.c. injection, although the response was considerably lower in comparison to the antibody response to wild type EtxB, with > 160 fold reduction in the mean antibody titer, 1050 versus

**SUBSTITUTE SHEET (RULE 26)**

-24-

171000, respectively. It is concluded that receptor binding by EtxB is essential for its potent immunogenicity *in vivo*.

Receptor binding does not influence the extent of lymphocyte proliferation in the presence of EtxB or EtxB(G33D)

The effect of EtxB or EtxB(G33D) on lymphocyte proliferation *in vitro* was examined. Lymphocytes were isolated from the popliteal and mesenteric lymph nodes (MLN) of mice immunized with either EtxB or EtxB(G33D) and stimulated *in vitro* with either protein, or with a heat-denatured preparation of EtxB or EtxB(G33D). The proliferative response of lymphocytes derived from the popliteal or MLN was similar. In each case, proliferation to each of the protein preparations increased with increasing B subunit concentration. A representative set of data from an experiment using MLN is shown in Table 1. The magnitude of the response to wild type and mutant pentamers was comparable as was that in the presence of heat-denatured wild type and mutant monomers. Figure 3 shows the kinetics of the proliferative responses obtained in the presence of 80  $\mu\text{g/ml}$  of each of the protein preparations. Reactivity was dependent on the presence of antigen, and followed a similar pattern in the presence of each protein. Reactivity was evident on day 3 of culture with incorporation of [ $^3\text{H}$ ]-Thd reaching a peak on day 4 and waning thereafter. The minor differences in the timing of peak responses apparent in Figure 3 were not observed in repeat experiments, showing that the anamnestic characteristics of the responses to the EtxB and EtxB(G33D) are comparable. It is concluded that the level of stimulation in the presence of the native proteins is not likely to be influenced by receptor binding or the introduced mutation.

Toxin receptor binding causes immunomodulation of B

SUBSTITUTE SHEET (RULE 26)

-25-

**cells and T cell subsets**

To examine if receptor binding by EtxB exerts any effect on the populations of lymphoid cells *in vitro*, lymphocytes were isolated from the MLN of mice primed  
5 i.p. with EtxB(G33D) and then stimulated with either EtxB or EtxB(G33D) or a mixture of both. Additionally, a parallel experiment using MLN-derived lymphocytes from mice injected with EtxB was undertaken and resulted in essentially identical findings to those  
10 obtained from EtxB(G33D) primed mice.

**(i) EtxB causes increased activation of B cells**

The effect of EtxB on B cells were examined by expression of the activation marker CD25 (IL-2R $\alpha$ ) in association with the B cell marker B220 (CD45R). As  
15 shown in Fig.4 the number of B cells in cultures stimulated with EtxB was 62.9% of total cells, of which a high proportion (28.4%) expressed the cell activation marker CD25. In contrast, the proportion of B cells after stimulation in the presence of EtxB(G33D) was  
20 less than half of that of the wild type (22.26%) and fewer were activated (5.6%). To establish whether the effects exerted by EtxB were dominant, cells were incubated in the presence of an equimolar concentration of EtxB and EtxB(G33D). The flow cytometric data was  
25 similar to that obtained following stimulation in the presence of wild type EtxB alone (with 60.6% B cells, of which 26% were activated). It is concluded that the receptor binding property of EtxB mediates an increased activation of B cells *in vitro*.

**30 (ii) EtxB causes increased activation of CD4<sup>+</sup> T cells and complete depletion of CD8<sup>+</sup> T cells.**

To examine the influence of B subunit receptor binding on T cells, lymphocytes were labelled with antibodies to CD4 or to CD8 in association with  
35 antibodies to CD25 (Fig.5). Additionally, some cells were separately labelled with antibodies to the CD3

-26-

marker (not shown). The proportion of T cells expressing the CD4 marker when stimulated in the presence of EtxB was 36.7%, of which a high proportion (32.7%) were activated. In contrast, no detectable CD8<sup>+</sup> T cells were present in the culture containing EtxB.

By comparison, both CD4<sup>+</sup> and CD8<sup>+</sup> T cells were present in the culture stimulated in the presence of EtxB(G33D). Such cultures contained a large proportion of CD4<sup>+</sup> T cells (66.6%), but only 12% of these were activated. The proportion of CD8<sup>+</sup> T cells detected in the presence of EtxB(G33D) was 11.7% of the total number of cells, but very few of these were activated which is indicated by the absence of the CD25 marker. Additionally, in the presence of a mixture consisting of an equimolar concentration of EtxB and EtxB(G33D) the pattern of responding cells was similar to that in the presence of wild type EtxB alone; with 41.68% CD4<sup>+</sup> T cells (of which 28.6% were CD25+) and no detectable CD8<sup>+</sup> T cells (Fig.5). In all these analyses, the proportion of cells staining with CD3 was approximately equal to the sum of those expressing CD4 and CD8 markers. These data demonstrate that the increase in activation of B and CD4<sup>+</sup> T cells and the selective depletion of CD8<sup>+</sup> T cells are mediated by toxin receptor occupancy.

#### 25 Production of cytokines

To assess whether the effect of EtxB on lymphocyte populations could be dependent on a change in cytokine production, cell cultures were incubated with either EtxB or EtxB(G33D) and supernatants removed on days 2, 3, 4, 5 and 6 for analysis. The results from samples collected on day 5 are shown in Table 2 when the maximum concentration of cytokines was detected. Both IFN- $\gamma$  and IL-2 were detected in the supernatants from cultures stimulated in the presence of EtxB or EtxB(G33D), although the relative levels of these cytokines varied. The medium from cells incubated with

-27-

wild type EtxB, contained a 3-fold higher concentration of IL-2 and a 1.5 fold lower level of IFN- $\gamma$  compared with supernatants from cultures stimulated in the presence of EtxB(G33D). Despite the finding that other  
5 proliferating T cell cultures responding to other antigens yielded high levels of IL-4, IL-5 and IL-10 none of these cytokines were detected in cultures stimulated with EtxB or EtxB(G33D). The increase in the level of IL-2 and decrease in the level of IFN- $\gamma$   
10 following stimulation with EtxB, compared with EtxB(G33D), most likely reflects the activation status of B and CD4<sup>+</sup> T cells. Nonetheless, the results indicate that the profound effect of wild type EtxB on the  
15 CD8<sup>+</sup> T cell population is unlikely to be mediated by a major shift in the cytokine profile, as a consequence of receptor occupancy.

#### Discussion

These investigations show that the introduction of  
20 a single point mutation (G33D) in the receptor binding site of EtxB caused a significant loss in the ability to bind GM1. Importantly, the mutant EtxB(G33D), exhibited identical physico-chemical properties to the wild type EtxB with respect to conformation, as  
25 revealed by gel chromatography, stability in SDS, acid and proteases. When the specific antibody responses were measured following immunization with either EtxB or EtxB(G33D), dramatic differences were noted. Subcutaneous injection with EtxB(G33D) in mice resulted  
30 in a highly significant drop in the antibody titer compared with wild type (ca >160 folds) while no antibody response was detected following oral administration. It is possible that these differences result from the disruption of a dominant epitope  
35 involved either in the recognition of the molecule by antibody, or the stimulation of effective T cell help

SUBSTITUTE SHEET (RULE 26)

-28-

for antibody production. However, it is noteworthy that the Gly to Asp substitution had no effect on the recognition of the B subunit by a panel of specific polyclonal and monoclonal antibodies. Further, the  
5 proliferative responses obtained when EtxB or EtxB(G33D) were added to cultures were comparable regardless of which of the proteins were used for *in vivo* priming; demonstrating that the T cell reactivity was not specific to either molecule. It is therefore  
10 concluded that receptor binding by EtxB is essential for its potent immunogenicity *in vivo*.

The importance of receptor binding in the potent immunogenicity of EtxB may be explained in a number of ways. Firstly, binding of the B subunit of Etx and Ctx  
15 to GM1 may increase the efficiency of uptake of these proteins, raising the local protein concentration available to the immune system. Other classes of proteins which are able to bind mucosal surfaces are found to be effective immunogens (De Aizpura, H.J. &  
20 Russell-Jones, G.J. (1988) *J. Exp. Med.* 167, 440- 451). The observed differences in the immunogenicity of EtxB and its mutant following oral administration may indeed be due to efficient uptake of EtxB from the lumen of the gut. However, the dramatic differences noted after  
25 parenteral immunization (where antigen is delivered locally at high concentration) are suggestive of other effects. For example, binding of EtxB to GM1 may affect the efficiency of antigen presenting cell activity. Such binding could cause activation of class  
30 II-bearing cells, particularly with respect to their expression of essential co-stimulatory molecules, such as B7, which is associated with their acquiring enhanced antigen presenting activity (Jenkins, M.K. & Johnson, J.G. (1993) *Curr. Opin. Immunol.* 5, 361-367).  
35 Alternatively, receptor binding may have direct effects on sub-populations of lymphocytes. A number of

SUBSTITUTE SHEET (RULE 26)

-29-

observations from this study provide strong evidence that this is indeed the case.

The *in vitro* studies demonstrated that EtxB was able to induce the proliferation of primed lymph node  
5 cells. This property was not dependent on receptor binding, since responses with similar anamnestic characteristics were obtained using either wild type EtxB, EtxB(G33D) or heat-denatured monomeric forms of these proteins which cannot bind GM1. These  
10 observations are interesting in themselves since it has been widely reported that commercial preparations of Ctx and CtxB or purified recombinant CtxB are strongly inhibitory of lymphocyte proliferation *in vitro*. The apparent discrepancy may have arisen from the fact that  
15 previous experiments had been conducted on purified lymphocytes and had largely used mitogen stimulated lymphocyte cultures (which are not clonally restricted responses), where a different mechanism may be involved. Consistent with this was our observation  
20 that the proliferation of Con A-stimulated lymphocytes was indeed inhibited by EtxB. However, the analyses of cell populations in cultures of primed lymph node cells stimulated with either EtxB or EtxB(G33D) revealed important differences with respect to B cells as well  
25 as CD4 and CD8-bearing T-cells.

B cells were detected after 4 days of culture in the presence of either EtxB or EtxB(G33D). However, by comparison with EtxB(G33D), the relative proportion of B cells present in cultures with EtxB was increased by  
30 approximately 100%. This increase was associated with the expression of CD25 on a very high proportion of the B cells. In the experiment shown, the responding lymphocytes were primed with EtxB(G33D) *in vivo*. Similar experiments with cells from EtxB immunized mice  
35 revealed comparable results. Thus, irrespective of any *in vivo* effects associated with receptor binding,

SUBSTITUTE SHEET (RULE 26)

-30-

cultures in the presence of EtxB contained a larger proportion of B cells compared with those stimulated with EtxB(G33D). These effects on B cells also appear not to be dependent, at least in part, on regulation by T cells, *in vitro*, as the results do not suggest a major shift in the profile of the detected cytokines. Therefore, *in vitro*, receptor binding by EtxB appears to be associated with a direct effect on B cells, resulting in proportional expansion of this population as well as their activation. It is also noteworthy that CtxB has been shown to increase expression of MHC class II on virgin B cells, a property which was not exhibited by a GM1 binding mutant CtxB (G33E) (Francis, M.L., Ryan, J., Jobling, M.G., Holmes R.K., Moss, J., & Mond J.J. (1992) J. Immunol. 148, 1999-2005). The results in these experiments suggest the presence of direct mitogenic effects by EtxB on antigen-primed B cells and demonstrate that such effects are mediated by receptor binding.

In addition to the effects of EtxB on B cells in culture, flow cytometric analyses reveal that this toxoid caused the complete depletion of any detectable CD8<sup>+</sup> cells. Once again, this effect was shown to be dependent on receptor binding, since this population of T cells were not depleted in cultures containing EtxB(G33D). Further, complete depletion of CD8<sup>+</sup> cells in cultures containing EtxB was observed, from mice immunized with wild type EtxB. There are three possible mechanisms by which such an effect may be mediated. 1) It is known that binding of Ctx or CtxB to GM1 on rat MLN cells induces patch and cap formation (Craig S.W. and Cuatrecasas P., (1975) Proc. Natl. Acad. Sci. USA, Vol.72, pages 3844-3848). It is possible that in this process EtxB-GM1 complexes and other molecules, including CD8, are internalized. Such a process would prevent flow cytometric detection of

SUBSTITUTE SHEET (RULE 26)



-31-

these cells using CD8 as a marker, and may result in their death due to the associated loss of the surface TCR complex. Although the latter may account for the absence of CD8<sup>+</sup> T cells in the culture, others found no

5 loss of the TCR complex from the surface of human Jarkat T cell line when CtxB was used (Imboden, J.B., Shoback, D. M., Pattison, G, & Stobo, J.D. (1986) Proc. Natl. Acad. Sci. USA 83, 5673-5677). Absence of

10 effects as a result of capping is supported by the finding that CD3 and CD4 markers were not affected. 2) An alternative mechanism would involve effects exerted by cytokines in culture. In this study, both IL-2 and IFN- $\gamma$  were detected. The results, however do not

15 suggest a major shift in the cytokine profile which would explain such a dramatic effect on CD8<sup>+</sup> T cells. 3) Absence of CD8<sup>+</sup> T cells may be due to active induction of apoptosis. Death of lymphocytes by apoptosis may involve capping as described above, or could be

20 mediated in the absence of capping by effects on the signalling events in the cell. Activation-induced programmed death is dependent on Ca<sup>2+</sup> and involves phosphatases and kinases. Binding of CtxB to lymphocytes has been shown to inhibit protein kinase C-dependent proliferation and induced a pronounced

25 increase in intra-cellular Ca<sup>2+</sup>, events which were not associated with an increase in CAMP level. The ability of EtxB to deplete CD8<sup>+</sup>, but not CD4<sup>+</sup> T cells could be due to differential effects of signals associated with the CD4/CD8-TCR complex, resulting from crosslinking

30 GM1 on the surface of these subset of lymphocytes. This could be as a result of differential binding of the toxoid on the membrane as reported for CtxB or alternatively to the differential signalling mechanisms in CD4<sup>+</sup> and CD8<sup>+</sup> T cells.

35 In the complete absence of detectable CD8<sup>+</sup> T cells, EtxB increased the proportion of CD4<sup>+</sup> T cells which were

SUBSTITUTE SHEET (RULE 26)

-32-

activated, by comparison with the receptor binding mutant. The essential requirement for CD4<sup>+</sup> T cells in response to Ctx has been demonstrated *in vivo*. The reason for the increased activation of this T cell subset is, however, unclear. It is noteworthy that CtxB has been shown to stimulate DNA synthesis and cell division in quiescent non-transformed mouse 3T3 cells. A selective mitogenic effect on CD4<sup>+</sup> T cells was also found in the presence of plant lectins which bind to Gal $\beta$ -1-3-3GalNAc, the same component that EtxB binds to in GM1. The possibility can not be ruled out that EtxB mediates a GM1-binding dependent direct effect on CD4<sup>+</sup> T cells, causing their activation. However, it is also possible that the increased activation of CD4<sup>+</sup> T cells in cultures containing EtxB is a consequence of those changes to the B cell and CD8<sup>+</sup> T cells populations described. B cell activation is known to be associated with an enhancement of their competency as antigen presenting cells for CD4<sup>+</sup> T cells. Further, CD8<sup>+</sup> T cells are widely associated with a regulatory role in immune reactivity both *in vivo* and *in vitro*. Their removal from T cell proliferative cultures has been associated with prolonged and enhanced levels of CD4<sup>+</sup> T cell division.

Taken together, the potent immunogenicity of EtxB *in vivo*, as shown in this study, can be suggested to occur as a result of its ability to increase activation of B cells exerted by growth regulating effects following binding to GM1. Activation of CD4<sup>+</sup> T cells and the ability of EtxB to increase production of IL-2 in culture *in vitro* may provide the necessary signal for further expansion of B cell clones. Depletion of CD8<sup>+</sup> T cells by EtxB *in vitro* in this study may also provide another mechanism of immunopotentiality *in vivo* following systemic or oral delivery, particularly in the light of the involvement of this subset of cells in

SUBSTITUTE SHEET (RULE 26)

-33-

suppression of the immune response and in oral tolerance. In this regard, both Ctx and Etx have been shown to abrogate oral tolerance to cofed soluble proteins and other studies implicated Ctx and CtxB depletion effects on intra-epithelial lymphocytes in the gut or in the dome of Peyer's patch to explain this mechanism. CtxB-inhibitory effects on CD8<sup>+</sup>T cells *in vitro* has also been shown to prevent graft versus host reaction.

10 In conclusion, it has been demonstrated that the presence of potent immunomodulatory effects by EtxB on the antibody response *in vivo*, and on populations of lymphocytes *in vitro*. Furthermore, it has been demonstrated that these effects are mediated by  
15 receptor binding. Our findings are also pertinent to an understanding of the ability of Etx and Ctx to act as potent adjuvants and as potential protein carriers for other antigens and suggest that such properties rely on the capacity of these toxoids to bind  
20 ganglioside receptors on the surface of lymphoid cells.

#### Example 2

This example illustrates that the effects on CD8 cells are irrespective of antigen recognition and are mediated by apoptosis.

25 Recombinant preparations of EtxB and EtxB(G33D) were prepared as in Example 1. Both proteins were well characterised with respect to binding to GM1, binding to a panel of monoclonal and polyclonal antibodies and various other physico-chemical properties. Ovalbumin  
30 (OVA) was purchased from Sigma (Poole, UK). Mesenteric lymph nodes (MLN) were isolated from BALB/c mice [high responder strain to EtxB (Nashar, T.O. and Hirst, T.R. 1995. Immunoregulatory role of H-2 and intra-H-2 alleles on antibody responses to recombinant  
35 preparations of B-subunits of *Escherichia coli* heat-labile enterotoxin (rEtxB) and cholera toxin (rCtxB).

SUBSTITUTE SHEET (RULE 26)

-34-

Vaccine 13:803.)) 8-10 weeks old. Mice were injected i.p. with 200µg of OVA (Sigma) emulsified in incomplete Freund's adjuvant (Sigma). MLN were removed 10 days after injection, minced through a stainless steel mesh into HBSS (Flow, Irvine, UK). The recovered cells were washed in HBSS by centrifugation (500 g, 10 min, 4°C) and resuspended in modified Eagle's medium (Flow) containing 20 mM HEPES, 100 IU penicillin, 100 µg/ml streptomycin, 4 mM L-glutamine and  $5 \times 10^{-5}$  M 2-mercaptoethanol (complete medium) to which 0.5% (v/v) of fresh autologous mouse serum was added. Cultures contained  $2 \times 10^6$  viable cells/ml in 2 ml volumes in 24-well plates (Nunc, Roskilde, Denmark) and were established in the presence of 100 µg/ml OVA (dialysed extensively in complete medium), either alone or with 40 µg/ml of EtxB or EtxB(G33D). Cultures were incubated at 37°C in 5% CO<sub>2</sub> and 95% air for 5 days. At desired time points, 0.1 ml samples were removed from the cultures and transferred to 96 well U-bottomed plates (Nunc) and pulsed with 1 µCi/well of [<sup>3</sup>H]thymidine (Amersham, UK) for 6 h before harvesting (Mach III harvesting 96; Tomtec, Orange, CT) and counting by standard liquid scintillation (1450 Micro b plus; LKB-Wallac, Turku, Finland). For flow cytometric analysis (Becton Dickinson, Erenbodegem-Aalst, Belgium) of T cells, cells were stained with the following rat antibodies (PharMingen, Cambridge, UK): FITC labelled anti-CD4 (RNRM4-5) or FITC- anti-CD8α (53-6.7) and with biotin-labelled anti-CD25 (IL-2Rα) (7D4) followed by Streptavidin-phycoerythrin. Additionally, for the biotin-labelled antibodies FITC-labelled Streptavidin was used. FACS analysis of recovered cells was performed on the peak day of proliferation (day 4), as determined by [<sup>3</sup>H]thymidine incorporation.

For apoptosis assays, fresh MLN cells (MLNC) and splenic T cells (SPLTC) were isolated from BALB/c mice,

SUBSTITUTE SHEET (RULE 26)

-35-

8-10 weeks old. MLNC comprising >90% CD3<sup>+</sup> T cells, as determined by flow cytometric analysis, were incubated for 2 h in petri dishes (Costar, Cambridge, MA) in complete medium containing 10% FCS, at 37° C in 5% CO<sub>2</sub> and 95% air to remove adherent cells. The non-adherent fraction was subsequently pipetted off, pelleted and washed twice in HBSS before use. SPLTC were purified by negative selection using glass beads coated with normal mouse serum followed by rabbit anti-mouse  $\gamma$ -globulins as described (Wigzell, H. 1976. Specific affinity fractionation of lymphocytes using glass or plastic bead columns. *Scand. J. Immunol.* 5:(suppl.5) 23.). The selected population of T cells were >90% CD3<sup>+</sup> as determined by flow cytometric analysis.

CD4<sup>+</sup> and CD8<sup>+</sup> T cells were separated as follows: non-adherent MLNC were labelled with rat phycoerythrin-anti-mouse CD4 (4708-02) or FITC-anti-mouse CD8 $\alpha$  (53-6.7) (PharMingen) and were then incubated with MACS colloidal super-paramagnetic microbeads conjugated with goat anti-rat IgG (H + L) F(ab')<sub>2</sub> (PharMingen), according to the manufacturer's instructions. These were applied to mini-MACS columns (Miltenyi Biotec, Bergisch Gladbach, Germany) in order to separate both positively (>99% pure) and negatively (>90% pure) selected populations of CD4 and CD8<sup>+</sup> T cells, as determined by flow cytometric analysis.

Two methods were used for quantification of apoptosis: i) staining DNA with acridine orange to examine nuclear morphology and, ii) cell cycle analysis following staining DNA with propidium iodide and with either anti-CD4 or anti-CD8 antibodies. Cultures of 2x10<sup>6</sup>/ml MLNC, SPLTC and fractionated MLNC were established in complete medium containing 10% FCS, in the absence or presence of 80  $\mu$ g/ml of either EtxB or EtxB(G33D) and examined from 4 to 18 h. Following incubation, cells were pelleted, washed with HBSS and

SUBSTITUTE SHEET (RULE 26)

-36-

stained with 5  $\mu\text{g/ml}$  acridine orange (Sigma). Thymocytes were isolated and treated in the absence or in the presence of  $10^{-7}\text{M}$  dexamethasone and used as a positive control for cells undergoing apoptosis.

5 Nuclear morphological changes in lymphocytes were examined by conventional or confocal fluorescence microscopy (Leica TCS 4D). The proportion of  $\text{CD4}^+$  and  $\text{CD8}^+$  SPLTC in the sub- $\text{G}_0/\text{G}_1$  stage of the cell cycle was determined by flow cytometric analysis of the DNA

10 content following staining with propidium iodide as described (O'Connor, P.M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I. and Kohn, K.W. 1993. Role of p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.

15 Cancer.Res. 53:4776.). Cells isolated from 18 h cultures of SPLTC incubated alone or with 40  $\mu\text{g/ml}$  EtxB or EtxB(G33D) were stained with FITC rat anti- $\text{CD4}$  or FITC-anti- $\text{CD8}\alpha$ . Stained cells were adjusted to  $1 \times 10^6/\text{ml}$  in cold HBSS containing 20mM HEPES and 0.5 mM EDTA and

20 were fixed with cold ethanol added dropwise. Then, 50  $\mu\text{g/ml}$  propidium iodide and 40  $\mu\text{g/ml}$  ribonuclease A (DNase free) were added, and the cells incubated for 1 h at room temperature. The relative intensity of DNA staining with propidium iodide in  $\text{CD4}$  and  $\text{CD8}^+$  T cells

25 was determined by gating on cells co-stained with each mAB.

In Example 1, the observation that  $\text{CD8}^+$  T cells are completely depleted from cultures of lymph node cells proliferating in response to EtxB suggested that EtxB

30 exerts a polyclonal effect on this T cell subset. To investigate whether such effects are dependent on the activation of EtxB responsive cells, cultures were established from CVA-primed mice and stimulated with

OVA alone or with OVA plus either EtxB or the mutant

35 EtxB(G33D). Similar peak levels of proliferation (day 4 of culture in each case) were achieved in the presence

SUBSTITUTE SHEET (RULE 26)

-37-

of OVA alone, OVA plus EtxB or OVA plus EtxB(G33D) (9734  $\pm$  347, 12,031  $\pm$  135 and 9305  $\pm$  290 c.p.m. respectively). However, there was a dramatic difference in the distribution of T cell subsets in these cultures after 4 days (Figure 6). All cultures contained CD4<sup>+</sup> T cells of which similar proportions co-expressed the activation marker CD25. However, CD8<sup>+</sup> T cells were undetectable in cultures incubated with OVA plus EtxB, but were clearly present (although not activated as assessed by CD25 expression) in cultures with OVA plus EtxB(G33D) or OVA alone. This establishes that EtxB induces depletion of CD8<sup>+</sup> T cells responding to an antigen other than EtxB. Moreover, the absence of such a response to EtxB(G33D) indicates that depletion is triggered following toxoid receptor interaction. It was also noted that the presence of wild-type EtxB caused a significant increase in the proportion of B cells of which a large number were CD25<sup>+</sup> (not shown) as had previously been found for EtxB responsive cultures (Example 1). It is therefore concluded that receptor occupancy by EtxB exerts profound immunomodulatory effects on lymphocytes irrespective of their antigen specificity.

The possibility that CD8<sup>+</sup> T cells undergo apoptosis when cultured in the presence of EtxB was investigated. MLNC or purified SPLTC, from unprimed mice, were incubated with EtxB or EtxB(G33D) and changes in cell nuclear morphology after staining with acridine orange were recorded over a period of 4 to 18 h (Table 3 and Figure 7). Cell morphological changes were characterized by the presence of condensation of chromatin resulting in the lobular appearance of the nucleus (Figure 7). Other cell features such as blebbing of the plasma membrane and the presence of apoptotic bodies were also observed. These morphological changes occurred in approximately one

SUBSTITUTE SHEET (RULE 26)

-38-

third of each of the cell preparations treated with EtxB, whereas a much lower incidence was observed in cells cultured with EtxB(G33D) or without exogenous antigen (Table 3). Since CD8<sup>+</sup> T cells accounted for  
5 -35-40% of the MLNC and SPLTC preparations, depletion of these cells could account for the observed apoptosis. To establish if this was the case, populations of purified CD8 and CD4<sup>+</sup> T cells were cultured for 18 h in the presence of antigens (Table  
10 3). Similar percentages of morphological changes were induced in negatively selected populations of CD4<sup>+</sup> T cells (containing >90% CD4-bearing cells) on treatment with either EtxB, EtxB(G33D) or no antigen, indicating that binding of EtxB to its receptor does not trigger  
15 apoptosis in this T cell subset. In contrast, >70% of the negatively selected CD8<sup>+</sup> T cells (>90% pure) exhibited morphological changes when cultured with wild-type EtxB; while incubation with either no antigen or EtxB(G33D) caused changes in only 11-19% of this T  
20 cell population, respectively. Further, the presence of low numbers of contaminating cells in the purified populations used (~10% in each case) could not account for the observed effects since more highly purified populations containing >99% of CD8 or CD4<sup>+</sup> T-cells  
25 (isolated by positive selection) responded to EtxB in a similar manner (60% were apoptotic in the presence of EtxB, compared with 7% for both no antigen and EtxB(G33D) treatments) (Table 3). Apoptosis was detected in 40% and 98% of thymocytes after 18 h  
30 incubation in the absence or in the presence of dexamethasone respectively.

To demonstrate that the morphological changes observed in our cultures were consistent with the induction of apoptosis, the appearance of subdiploid  
35 DNA in cultures of SPLTC treated for 18 h with EtxB was evaluated. Cells were subjected to flow cytometric

SUBSTITUTE SHEET (RULE 26)



-39-

analysis after co-staining with propidium iodide and either anti-CD8 or anti-CD4 antibodies (Figure 8). Approximately 48 % of the CD8<sup>+</sup> T cells from cultures incubated with EtxB fell below the diploid G<sub>0</sub>/G<sub>1</sub> peak of propidium iodide staining, indicating that they were undergoing apoptosis (O'Connor, P.M. et al, *supra*). A small proportion of cells expressing CD4, in cultures with EtxB, also exhibited sub-G<sub>0</sub>/G<sub>1</sub> levels of DNA (~11%; which may result from the death of such a high proportion of CD8<sup>+</sup> T cells). In contrast, the majority of CD4 or CD8<sup>+</sup> T cells cultured without antigen or in the presence of EtxB(G33D) were in G<sub>0</sub>/G<sub>1</sub> phase of the cell cycle, with <5% exhibiting apoptosis. We conclude that the observed nuclear morphological changes, and the presence of sub-G<sub>0</sub>/G<sub>1</sub> levels of DNA, in a substantial proportion of CD8<sup>+</sup> T cells treated with EtxB demonstrate a selective apoptosis triggered by the cholera-like enterotoxoid. The failure of the receptor binding mutant, EtxB(G33D), to induce similar effects demonstrates that the induction of CD8<sup>+</sup> T cell apoptosis is linked to its ability to bind to GM1 ganglioside.

### Example 3

Groups of 8 male DBA/1 mice were either unchallenged (group A) or were each injected with 100µg of bovine collagen in CFA on day 0 by intra-dermal (i.d.) injection into the flank. Collagen injected mice were either left unprotected (group B; positive control) or attempts were made to prevent disease development by the administration i.d. at an adjacent site to collagen challenge of; 100µg of EtxB in IFA on day 0 (group C), 100µg of EtxB in IFA on day 14 (group D), or 100µg EtxB(G33D) in IFA on day 0 (group E). All animals, except those in group A, received a boosting dose of collagen in IFA i.d. on day 21, and disease severity was assessed on day 45 by measuring hind limb ankle thickness (experiment A) or scoring each hind

-40-

limb digit for swelling (scale 0-3 where 0 = normal, and 3 = maximal swelling; experiment B).

The results obtained are illustrated in Figures 9a and 9b. These show that EtxB, but not EtxB(G33D),  
5 dramatically protects mice from the development of collagen-induced arthritis.

#### Example 4a

Two separate human buffy coat samples (obtained from normal human blood donors) were used as a source  
10 of mononuclear cells. Cells were isolated over Ficoll-paque and washed extensively before culture in the absence of antigen or with 80µg/ml of either EtxB or EtxB(G33D) as indicated. Prior to culture the cell  
populations comprised 24% CD8+, 27% CD4+ and 27% CD8+,  
15 22.9% CD4+ for each sample respectively. After culture for 18 hours the appearance of apoptotic cells was assessed in samples of cells stained with acridine orange (as detailed under Example 2). The results  
obtained are shown in Figure 10; these illustrate that  
20 EtxB but not EtxB(G33D) induces apoptosis in a population of normal human peripheral blood mononuclear cells.

#### Example 4b

The murine T cell line, CTLL-2, was cultured to  
25 confluence and then the cells washed before being reseeded at  $1 \times 10^6$  cells/ml in the absence of antigen or with 80µg/ml of either EtxB or EtxB(G33D) as indicated. After 18 hours samples were removed and the percentage of cells showing signs of apoptosis was  
30 assessed using acridine orange (detailed under Example 2). The results obtained are illustrated in Figure 11. They show that cross-linking of GM1 leads to apoptosis in a proportion of murine CTLL cells.

SUBSTITUTE SHEET (RULE 26)

-41-

Table 1 - Lymphocyte proliferation in the presence of  
EtxB or EtxB (G33D)

	<u>Dose <math>\mu</math>g/ml</u>	<u>EtxB</u>	<u>EtxB(G33D)</u>	<u>EtxB*</u>	<u>EtxB(G33D) *</u>
	0	117.9 (7.9)	146.8 (3.5)	124.5 (14.6)	116.1 (6.35)
5	5	4928 (98.7)	2860 (3.8)	2424 (88.3)	1431.5 (37.5)
	10	6978 (30.6)	3681 (4.6)	2518 (21.6)	4231 (96.4)
	20	7084 (100)	6912 (47.3)	4394 (42.1)	5075 (24.8)
	40	8844 (26)	8586 (143.7)	7431 (45.3)	4368.5 (118.9)
	80	10246 (30.7)	12510 (121.8)	7986 (210.3)	7276 (369.5)
10	160	11311 (247)	13525 (352.7)	-----	-----

Mice were injected i.p. with 30 $\mu$ g of EtxB (G33D) in complete Freund's adjuvant (CFA). Mesenteric lymph nodes were isolated 10 days later. Cells were isolated and incubated for 4 days in the presence of EtxB, EtxB (G33D) or disassembled monomeric forms of these proteins (\*), generated by heating at 95°C. Proliferation was determined by addition of 1 $\mu$ Ci of (<sup>3</sup>H) dThd for the last 6 hours on day 4. Data represents mean cpm and SEM of triplicate wells. Cells isolated from unimmunized mice gave <1500 cpm (dose 160 $\mu$ g/ml).

Table 2 - Cytokine analysis in the presence of EtxB or  
EtxB (G33D)

	<u>Protein</u>	<u>IL-2 (pg/ml)</u>	<u>IFN-<math>\gamma</math> (pg/ml)</u>
25	EtxB	318	2700
	EtxB (G33D)	67	4068

Mice were injected with EtxB (G33D) in CFA and mesenteric lymph nodes cells were isolated 10 days later. Cells were then incubated in vitro with either

**SUBSTITUTE SHEET (RULE 26)**

-42-

EtxB or EtxB(G33D) and samples of supernatants analysed for cytokine content on day 5 of cellular proliferation.

5            Table 3 - EtxB-receptor mediated apoptosis in  
                  fractionated lymphocytes.

	Cells	Time (h)	No antigen	EtxB(G33D)	EtxB
	MLNC	4	0 <sup>a</sup> (8)	2 (0)	1 (3)
		18	8 (10)	5 (18)	29 (35)
10	SPLTC	4	3 (7)	2 (6)	3 (5)
		18	17 (5)	16.5 (12)	31 (32)
	Negative selection				
	CD4	18	5 (37)	6 (31)	9 (35)
	CD8	18	18 (11)	19 (15)	76 (73)
15	Positive selection				
	CD4	18	6	4	6
	CD8	18	7	7	60

- 20 Nuclear morphological changes in fractionated CD4 and CD8<sup>+</sup> T cells after 4 or 18 h incubation in the absence of antigen, or with 80 µg/ml of EtxB or EtxB(G33D) were examined by fluorescence microscopy following staining with acridine orange. Whole MLN were depleted of
- 25 adherant cells. SPLTC were isolated by negative selection in glass beads column coated with mouse γ-globulins and rabbit anti-mouse as a secondary antibody. Fractionated SPLTC were obtained following labelling with rat phycoerythrin-anti-mouse CD4 or
- 30 FITC-anti-mouse CD8α which were then incubated with MACS colloidal super-paramagnetic microbeads conjugated with goat anti-rat IgG (H + L) F(ab')<sub>2</sub>. These were separated using mini-MACS columns to obtain both the positively (>99% pure) and negatively (>90% pure)
- 35 selected fractions of CD4 and CD8<sup>+</sup> T cells. Nuclear morphological changes were examined from 4 to 18 h in a random sample of 200 cells per treatment as described in the legend to Fig. 7. Maximum percentage of

-43-

apoptotic cells occurred after 18 h. The data in brackets when indicated represent results from another separate experiment. Data for MLN and SPLTC are representative of a total of four experiments.

5 \*Percentage apoptotic cells

**SUBSTITUTE SHEET (RULE 26)**

CLAIMS:

1. For use as an agent in the treatment or the prevention of an autoimmune disease:
  - (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or
  - (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity.
2. The use of Ctx, Etx or the B subunit of Ctx or Etx, for the manufacture of a medicament for use as an agent for the treatment or the prevention of an autoimmune disease.
3. A method for treating an autoimmune disease in which an effective amount of an agent selected from:
  - (i) an agent having GM-1 binding activity; or
  - (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;is administered to a mammalian subject.
4. A method according to claim 3, wherein said agent is co-administered with a self or cross-reacting antigen.
5. A pharmaceutical composition for the treatment of a mammalian autoimmune disease comprising:
  - (i) an agent having GM-1 binding activity; or
  - (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;and a pharmaceutically acceptable carrier or diluent therefor.
6. A pharmaceutical composition according to claim 5, further comprising self- or cross-reacting antigenic determinant.
7. A kit comprising a pharmaceutical composition in accordance with claim 5 and separate therefrom a

-45-

pharmaceutical composition comprising self- or cross-reacting antigenic determinant.

8. For use in the treatment of human leukaemias of a T cell origin:

- 5 (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or  
(ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity.

10 9. The use of Ctx or Etx, or the B subunits of Ctx and Etx for the manufacture of a medicament for treatment of human leukaemias of a T cell origin.

10. A method for treating a human leukaemia of a T cell origin in which an effective amount of an agent  
15 selected from:

- (i) an agent having GM-1 binding activity; or  
(ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;

20 is administered to a mammalian subject.

11. A pharmaceutical composition for the treatment of human leukaemias of a T cell origin comprising:

- (i) an agent having GM-1 binding activity; or  
25 (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;

and a pharmaceutically acceptable carrier or diluent therefor.

30 12. For use as a therapeutic agent for the prevention/treatment of transplant rejection or GVHD:

- (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or  
35 (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1

**SUBSTITUTE SHEET (RULE 26)**

-46-

binding activity.

13. The use of Ctx or Etx or the B subunit of Etx or Ctx for the manufacture of a medicament for the prevention of transplant rejection or GVHD.

5 14. A method for the prevention or treatment of transplant rejection or GVHD in which an effective amount of an agent selected from:

- (i) an agent having GM-1 binding activity; or
- 10 (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;

is administered to a mammalian subject.

15. For use in the vaccination of a mammalian subject:

- 15 (i) an agent having GM-1 binding activity, other than Etx or Ctx or the B subunits of Etx or Ctx; or
- (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1
- 20 binding activity.

16. A method for the vaccination of a mammalian subject in which an effective amount of an agent selected from:

- 25 (i) an agent having GM-1 binding activity other than Ctx and Etx; or
- (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity;

is co-administered to a mammalian subject with an


30 effective amount of an unrelated foreign antigenic determinant.

**SUBSTITUTE SHEET (RULE 26)**





1 / 11

FIG. 1a



SUBSTITUTE SHEET (RULE 26)

2 / 11



SUBSTITUTE SHEET (RULE 26)

3 / 11




FIG. 2

4 / 11




FIG. 3

5 / 11




FIG. 4

SUBSTITUTE SHEET (RULE 26)

6 / 11




FIG. 5

SUBSTITUTE SHEET (RULE 26)

7 / 11





FIG. 6

SUBSTITUTE SHEET (RULE 26)

8 / 11

EtxB(6330)



EtxB





FIG. 7

SUBSTITUTE SHEET (RULE 26)



9 / 11

FIG. 8



SUBSTITUTE SHEET (RULE 26)

10 / 11




FIG. 9b




FIG. 9a

11 / 11

FIG. 10



GM1-MEDIATED APOPTOSIS OF HUMAN  
PERIPHERAL BLOOD MONONUCLEAR CELLS

FIG. 11

GM1-MEDIATED APOPTOSIS OF AN  
IMMORTALISED MURINE T-CELL LINE, CTLL

SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

Application No  
PCT/GB 96/01614

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K39/00 C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93 (1). 1996. 226-230. ISSN: 0027-8424, XP002019422	1-16
Y	NASHAR T O ET AL: "Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: Receptor binding is essential and induces differential modulation of lymphocyte subsets." see pages 229-230, paragraph "Discussion"	1-16
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

25 November 1996

Date of mailing of the international search report

17.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Halle, F

# INTERNATIONAL SEARCH REPORT

Internati. Application No  
PCT/GB 96/01614

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	INTERNATIONAL IMMUNOLOGY 8 (5). 1996. 731-736. ISSN: 0953-8178, XP002019423 NASHAR T O ET AL: "Cross-linking of cell surface ganglioside GM1 induces the selective apoptosis of mature CD8+ T lymphocytes." see page 733, right-hand column, last paragraph - page 735, right-hand column, last line	1-16
Y	--- THE JOURNAL OF IMMUNOLOGY, vol. 154, 1995, pages 3611-3617, XP002019424 B. YANKELEVICH ET AL.: "Prevention of Acute Graft-Versus-Host Disease" see pages 3615-3617, paragraph "Discussion"	1-16
Y	--- WO,A,95 10301 (HOLMGREN JAN ;CZERKINSKY CECIL (SE)) 20 April 1995 see page 9, line 7 - page 9, line 16; claim 5 -----	1-16

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 96/ 01614

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 3, 4, 10, 14, 16  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internati. Application No

PCT/GB 96/01614

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9510301	20-04-95	AU-A- 7867194	04-05-95
		CA-A- 2173254	20-04-95
		EP-A- 0722340	24-07-96
		SE-A- 9303301	09-04-95
-----			

**THIS PAGE BLANK (USPTO)**